Pharma Journalist 8947 posts 0 comments

Novartis announced full results from its global Phase III PARAGON-HF study, investigating the efficacy and safety of Entresto (sacubitril/valsartan) versus the active comparator…
Read More...

At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Discovery Summit returns to reunite the leading minds from…
Read More...

SMi Reports: Mike Page, Executive Director Global Regulatory Affairs Portfolio Products at Alexion Pharmaceuticals invites heads of medical affairs and all who are interested to SMi’s…
Read More...

Ajinomoto Bio-Pharma Services announced its intention to purchase the remaining 50 percent ownership interest in its Visakhapatnam, India joint venture, Granules OmniChem Private…
Read More...

Roche announced that the European Commission has approved Tecentriq (atezolizumab) plus chemotherapy (Abraxane ) for the treatment of adult patients with unresectable locally advanced…
Read More...

AstraZeneca announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary endpoint,…
Read More...

AbbVie announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit at a…
Read More...

Esperion announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study (1002-058). This was a randomized, double-blind, parallel group study…
Read More...

La Jolla Pharmaceutical Company, a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering…
Read More...

PCI Pharma Services (PCI) has solidified its leadership position in the EU with strategic investment to deepen its presence in Ireland and expand its European foothold. PCI has…
Read More...